用于治疗耐火性心痛的冠状动脉缩剂 (ORBITA- COSMIC):随机对照试验
在PubMed上查看摘要
概括
此摘要是机器生成的。冠状动脉缩小剂 (CSR) 在稳定冠状动脉疾病患者中改善了胸痛症状,但没有增强心肌输液. 这为耐火症患者提供了一种新的抗血管选择.
科学领域
- 心脏病学
- 干预心脏病学
- 医疗器械
背景情况
- 稳定性冠状动脉疾病 (CAD) 通常会导致心痛,影响生活质量.
- 冠状动脉缩剂 (CSR) 的目的是改善心肌输液并减少心痛.
- 现有的治疗可能对一些耐火性心痛患者来说不足.
研究的目的
- 评估与安慰剂相比CSR在减少心肌缺血的疗效.
- 评估CSR对心痛症状和生活质量的影响.
- 为CSR提供证据作为潜在的抗血管治疗.
主要方法
- 这是一项双盲,随机,安慰剂对照试验.
- 包括患有稳定的CAD,缺血和耐性心痛患者.
- 评估包括心脏MRI,症状问卷和跑步机测试,每天通过智能手机应用报告症状.
主要成果
- 与安慰剂相比,CSR在缺血段中没有显著改善心肌血流.
- 接受CSR治疗的患者报告每日心痛发作显著减少.
- 发生了两例CSR栓塞;没有报告急性冠状动脉综合征或死亡.
结论
- 在稳定的CAD患者中,CSR装置有效降低了胸痛症状.
- CSR 没有改善心肌膜外输液.
- 对于某些患者来说,CSR是一种可行的额外抗血管治疗选择.
相关概念视频
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

